Crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and a process for the preparation thereof is disclosed, wherein the process comprises: (a) dissolving a salt of R(+)-N-propargyl-1-aminoindan in water to form a solution (b) cooling said solution to a temperature of about 15 Deg. C(c) basifying said solution to a pH of about 11 to form a suspension and(d) obtaining said crystalline rasagiline R(+)-N-propargyl-1-aminoindan from the suspension. Also disclosed is a process for the manufacture of crystalline R(+)-N-propargyl1-aminoindan comprising: (a) obtaining a first organic solution of liquid R (+) -Npropargyl-1-aminoindan(b) completely evaporating the solvent from the first organic solution under vacuum to form a residue (c) dissolving the residue in a second organic solvent to form a second organic solution (d) completely evaporating the second organic solvent from the second organic solution under vacuum to form a second residue and (e) maintaining the second residue at a temperature between 0 and 25 Deg. C to form crystalline R(+)-N-propargyl-1-aminoindan.
